Rather than reprinting the newsletter, I will direct you to it and let your read it. Living Cell Technologies is fast out pacing the rest of the world in cell therapies for diabetes and may soon have products in Japan, China, and other countries.
The biggest plus is the lack of need for the use of any immunosuppression. As a person with type 2 diabetes, this is still very exciting news and especially for those that are type 1 and hypoglycemically unaware.
I am posting this on both of my blogs.
Showing posts with label DIABECELL. Show all posts
Showing posts with label DIABECELL. Show all posts
10 August 2011
01 March 2011
LCT Granted Australian Patent
In a press release, Living Cell Technologies announced it has been granted a patent by the Australian Patent Office for IMMUPEL™. This is the industry leading technology for encapsulating living cells prior to transplantation. The granting of the Australian patent provides protection of this crucial intellectual property in advance of possible future clinical trials in Australia. What country will be next?
This selectively permeable system protects encapsulated living cells from immune rejection without the need for immunnosuppressant drugs, while at the same time allowing the transplanted cells to survive and function normally.
This technology has been demonstrated in Russia and in an on-going Phase II clinical trial in New Zealand, the IMMUPEL platform, as used in LCT's DIABECELL® product, has facilitated the effective transplantation of insulin-secreting porcine pancreatic cells into diabetes patients. Russia has approved its use.
Living Cell Technologies' product is the first to show clear efficacy in humans using encapsulated cells derived from another species, in this case from pigs.
So for readers in Australia watch for clinical trials. For those that want further information and to follow press releases, bookmark this. Use the contact to request information.
This selectively permeable system protects encapsulated living cells from immune rejection without the need for immunnosuppressant drugs, while at the same time allowing the transplanted cells to survive and function normally.
This technology has been demonstrated in Russia and in an on-going Phase II clinical trial in New Zealand, the IMMUPEL platform, as used in LCT's DIABECELL® product, has facilitated the effective transplantation of insulin-secreting porcine pancreatic cells into diabetes patients. Russia has approved its use.
Living Cell Technologies' product is the first to show clear efficacy in humans using encapsulated cells derived from another species, in this case from pigs.
So for readers in Australia watch for clinical trials. For those that want further information and to follow press releases, bookmark this. Use the contact to request information.
18 February 2011
Money Pledged for Final Phase II NZ Porcine Trial
DIABECELL now has the money pledged to the final participants in their phase II trial. Two international charitable foundations, New Zealand-based Cure Kids and U.S.-based Children with Diabetes Foundation, have each pledged to provide US $140,000 to fund the final two patients in a Phase II clinical trial in New Zealand that may well transform the treatment of Type 1 diabetes.
The trial is testing DIABECELL as a treatment for Type 1 diabetes and has been developed by Living Cell Technologies, an Australian company domiciled in New Zealand. DIABECELL is designed to help normalize the lives of people with unstable Type 1 diabetes, especially those suffering from life-threatening episodes of unaware hypoglycemia. Tiny DIABECELL micro-spheres containing live islet cells are implanted into a patient's abdomen using a simple laparoscopic procedure.
Once implanted, DIABECELL works by self-regulating and efficiently secreting insulin in response to the patient's changing glucose levels. DIABECELL islets are protected from the body's immune response by LCT's breakthrough proprietary encapsulation technology, so DIABECELL patients do not require any immunosuppression.
To date, twelve of the approved New Zealand patients with unstable insulin dependent diabetes have received this ground-breaking treatment, which has been shown to safely improve diabetes management and reduce or eliminate episodes of life-threatening low blood glucose levels. The dramatic results to date show DIABECELL’s ability to ameliorate this serious complication of diabetes, known as hypoglycemic unawareness, is an important potential benefit to patients.
Read the full press release here from February 16, 2011.
The trial is testing DIABECELL as a treatment for Type 1 diabetes and has been developed by Living Cell Technologies, an Australian company domiciled in New Zealand. DIABECELL is designed to help normalize the lives of people with unstable Type 1 diabetes, especially those suffering from life-threatening episodes of unaware hypoglycemia. Tiny DIABECELL micro-spheres containing live islet cells are implanted into a patient's abdomen using a simple laparoscopic procedure.
Once implanted, DIABECELL works by self-regulating and efficiently secreting insulin in response to the patient's changing glucose levels. DIABECELL islets are protected from the body's immune response by LCT's breakthrough proprietary encapsulation technology, so DIABECELL patients do not require any immunosuppression.
To date, twelve of the approved New Zealand patients with unstable insulin dependent diabetes have received this ground-breaking treatment, which has been shown to safely improve diabetes management and reduce or eliminate episodes of life-threatening low blood glucose levels. The dramatic results to date show DIABECELL’s ability to ameliorate this serious complication of diabetes, known as hypoglycemic unawareness, is an important potential benefit to patients.
Read the full press release here from February 16, 2011.
25 January 2011
Russia First to Approve Marketing of Porcine Cells
This may not be approved for people with diabetes, Type 2, it is well worth reading and following the results obtained. This is presently for those with Type 1 diabetes and represents the first actual use of porcine cells in any country outside of the trials. Russia has approved this for human use.
I had hoped for more press, but over a month has passed and nothing. For people with Type 1 diabetes, this has to be very hopeful. The US will probably take several years to even consider this, but this is very hopeful and should be followed closely. I have tried to find out what stage the University of Minnesota is at in their trials, but emails have not been returned, or never received – two were returned, but the third one I have nothing on.
Living Cell Technologies (LCT) is the first company to have clinical trials using porcine cells implants. These implants are implanted in the abdomen using a simple laparoscopic procedure. Then the “DIABECELL” (LCTs registered trademark) implants work by self regulating and efficiently secreting insulin and glucagon in response to the patient's changing glucose levels. Using their own LCT proprietary encapsulation, the DIABECELL patients do not require any immunosuppression or anti-rejection drugs.
LCT has a web site here with a press release and other related areas that are excellent to read. Then a Type 1 blogger from New Zealand has this to say about progress in New Zealand.
I had hoped for more press, but over a month has passed and nothing. For people with Type 1 diabetes, this has to be very hopeful. The US will probably take several years to even consider this, but this is very hopeful and should be followed closely. I have tried to find out what stage the University of Minnesota is at in their trials, but emails have not been returned, or never received – two were returned, but the third one I have nothing on.
Living Cell Technologies (LCT) is the first company to have clinical trials using porcine cells implants. These implants are implanted in the abdomen using a simple laparoscopic procedure. Then the “DIABECELL” (LCTs registered trademark) implants work by self regulating and efficiently secreting insulin and glucagon in response to the patient's changing glucose levels. Using their own LCT proprietary encapsulation, the DIABECELL patients do not require any immunosuppression or anti-rejection drugs.
LCT has a web site here with a press release and other related areas that are excellent to read. Then a Type 1 blogger from New Zealand has this to say about progress in New Zealand.
Subscribe to:
Posts (Atom)